# US 2021/0275648 A1 · Southern cattle tick vaccine product

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275648 A1
- Document ID: US20210275648A1
- Status: Published application
- Kind: A1
- Application number: 17/190,235
- Filed: 2021-03-02
- Published: 2021-09-09
- Earliest claimed: 2020-03-03
- Assignees: The United States of America as represented by the Secretary of Agriculture
- Applicants: The United States of America, as represented by the Secretary of Agriculture
- Inventors: ADALBERTO A PEREZ DE LEON; ROBERT E BRIGGS; FRED M TATUM; Robert Miller; Felicito Guerrero
- Web page: https://patentgrep.com/patent/US20210275648A1

## CPC

- A61K 39/0003: {Invertebrate antigens}
- A61K 39/08: Clostridium, e.g. Clostridium tetani
- A61P 33/14: Ectoparasiticides, e.g. scabicides
- C07K 14/285: from Pasteurellaceae (F), e.g. Haemophilus influenza
- C07K 14/33: from Clostridium (G)
- C07K 14/43527: {from ticks}
- A61K 2039/523: {expressing foreign proteins}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This invention relates to novel fusion peptides and immunogenic compositions containing the fusion peptides useful in the control and prevention of tick infestations. The invention also relates to compositions comprising said fusion peptides, methods of vaccination against tick infestation using said fusion peptides and compositions, and kits for use with such compositions and methods.

## Claims

### Claim 1

A polynucleotide encoding at least one copy of a tick aquaporin 1 protein (AQP1) fragment and a at least one copy of a tetanus toxin P2 epitope (P2 epitope).

### Claim 2 (depends on 1)

The polynucleotide of claim 1, where in the tick AQP1 fragment is a R. microplus AQP1 (RmAQP1) fragment.

### Claim 3 (depends on 1)

The polynucleotide of claim 1, wherein the polynucleotide encodes two copies of the AQP1 fragment.

### Claim 4 (depends on 1)

The polynucleotide of claim 1, wherein the polynucleotide encodes two copies of the P2 epitope.

### Claim 5 (depends on 1)

A composition comprising the polynucleotide of claim 1.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the composition is a polynucleotide, a plasmid, an expression vector, a host cell, a vaccine, or an immunogenic composition.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the composition is a replacement plasmid, an attenuated M. haemolytica strain A1 bacterium, or an attenuated M. haemolytica strain A6 bacterium.

### Claim 8 (depends on 1)

A vaccine or immunogenic composition comprising the polynucleotide of claim 1, and optionally an adjuvant.

### Claim 9 (depends on 5)

A method of provoking an immune response in an animal, the method comprising administering to the animal at least one effective dose of a composition of claim 5.

### Claim 10 (depends on 9)

The method of claim 9, wherein the animal is a mammal.

### Claim 11 (depends on 1)

A modified M. haemolytica lktCA gene cluster cassette comprising an insertion of a polynucleotide encoding an additional leukotoxin neutralizing epitope and the polynucleotide of claim 1 inserted downstream of the native leukotoxin A start codon.

### Claim 12 (depends on 11)

A composition comprising the modified M. haemolytica lktCA gene cluster cassette of claim 11.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the composition is a polynucleotide, a plasmid, an expression vector, a host cell, a vaccine, or an immunogenic composition.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the composition is a replacement plasmid, an attenuated M. haemolytica strain A1 bacterium, or an attenuated M. haemolytica strain A6 bacterium.

### Claim 15 (depends on 11)

A vaccine or immunogenic composition comprising the modified M. haemolytica lktCA gene cluster cassette of claim 11, and optionally an adjuvant.

### Claim 16 (depends on 12)

A method of provoking an immune response in an animal, the method comprising administering to the animal at least one effective dose of a composition of claim 12.

### Claim 17 (depends on 16)

The method of claim 16, wherein the animal is a mammal.

### Claim 18 (depends on 1)

A kit comprising the polynucleotide of claim 1.

### Claim 19 (depends on 5)

A kit comprising the composition of claim 5.

### Claim 20 (depends on 11)

A kit comprising the modified M. haemolytica lktCA gene cluster cassette of claim 11.

### Claim 21 (depends on 12)

A kit comprising a composition of claim 12.
